SITABITE D 100/10 TAB 10S

About

Sitabite D 100/10 is a fixed-dose combination medication designed for the advanced management of Type 2 Diabetes Mellitus, comprising Sitagliptin, a DPP-4 inhibitor, and Dapagliflozin, an SGLT2 inhibitor. Sitagliptin functions by inhibiting the enzyme dipeptidyl peptidase-4, which in turn elevates the circulating levels of active incretin hormones, such as GLP-1 and GIP. These hormones play a vital role in enhancing glucose-dependent insulin secretion from pancreatic beta cells and suppressing glucagon secretion from alpha cells. Dapagliflozin acts independently of insulin by inhibiting the sodium-glucose co-transporter 2 (SGLT2) in the kidneys, leading to reduced glucose reabsorption and increased urinary glucose excretion. This unique dual mechanism provides comprehensive glycemic control, addressing multiple pathophysiological defects in Type 2 diabetes, and offers additional benefits such as modest weight reduction and demonstrated cardiovascular and renal protective effects, making it a valuable option for many patients.

Uses

• Management of Type 2 Diabetes Mellitus.
• To improve glycemic control.
• Used as an adjunct to diet and exercise.
• To reduce the risk of cardiovascular events in certain patients.

Directions For Use

Take this medication orally, once daily in the morning, with or without food. Ensure adequate hydration while on this medication.

Benefits

• Provides effective blood sugar control through two distinct mechanisms.
• Reduces HbA1c levels significantly.
• May lead to modest weight loss.
• Offers cardiovascular and renal benefits (Dapagliflozin component).
• Low risk of hypoglycemia when used alone.
• Convenient once-daily dosing.

Side Effects

• Urinary tract infections
• Genital yeast infections
• Nasopharyngitis
• Headache
• Diarrhea
• Nausea
• Increased urination
• Dizziness
• Back pain
• Hypotension (low blood pressure)
• Ketoacidosis (rare, serious with SGLT2 inhibitors)
• Pancreatitis (rare, serious with DPP-4 inhibitors)

Safety Measures

• Alcohol - Excessive alcohol intake can increase the risk of dehydration and ketoacidosis, especially with SGLT2 inhibitors. Moderate consumption is advised.
• Pregnancy - Not recommended during pregnancy, especially during the second and third trimesters, due to potential risks to fetal kidney development.
• Breastfeeding - Not recommended during breastfeeding as it is unknown if the components pass into breast milk and could harm the infant.
• Liver - Use with caution in patients with liver impairment. Dose adjustment may be needed for sitagliptin in severe cases.
• Kidney - Dapagliflozin is not recommended in severe kidney impairment. Sitagliptin requires dose adjustment based on kidney function.
• Lung - No specific contraindications or precautions related to lung conditions are typically noted for this combination.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.